Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomised controlled treatment trials

Article English OPEN
Fineberg, N ; Stein, DJ ; Premkumar, P ; Carey, P ; Sivakumaran, T ; Vythilingum, B ; Seedat, S ; Westenberg, H ; Denys, D (2006)

Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive–compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized placebo-controlled studies looking at the addition of the second-generation antipsychotic quetiapine in such cases. Three studies fulfilled the inclusion criteria. Altogether 102 individuals were subjected to analysis using Review Manager (4.2.7). The results showed evidence of efficacy for adjunctive quetiapine (< 400 mg/day) on the primary efficacy criterion, measured as changes from baseline in total Yale–Brown Obsessive Compulsive Scale scores (P = 0.008), the clinical significance of which was limited by between-study heterogeneity. The mechanism underlying the effect may involve serotonin and/or dopamine neurotransmission.
  • References (27)
    27 references, page 1 of 3

    Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002). Quetiapine augmentation in patients with treatment-resistant obsessive compulsive disorder. A single blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119.

    Bogan AM, Koran LM, Chuong HV, Vapnik T, Bystritsky A (2005). Quetiapine augmentation in obsessive compulsive disorder resistant to serotonin reuptake inhibitors: an open label study. J Clin Psychiatry 66:73-79.

    Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005). Quetiapine augmentation of SRIs in treatment refractory obsessivecompulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry 5:5.

    Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR (2005). The use of aripiprazole in obsessive compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66:49-51.

    Cochrane Collaboration (2004). Review Manager 4.2.7. Available at: http:// www.cc-ims.net/RevMan.

    Denys D, van Megen H, Westenberg H (2002). Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder; an open label study. J Clin Psychiatry 63:700-703.

    Denys D, de Geus F, van Megen HJGM, Westenberg HGM (2004a). A doubleblind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.

    Denys D, Klompmakers AA, Westenberg HG (2004b). Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berlin) 176:195-203.

    Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-030.

    Fineberg NA, Gale T (2005). Evidence-based pharmacological treatments for obsessive compulsive disorder. Int J Neuropsychopharmacol 8:107-129.

  • Metrics
    0
    views in OpenAIRE
    0
    views in local repository
    98
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    Institutional Repository - IRUS-UK 0 98
Share - Bookmark